Nektar Therapeutics (NASDAQ: NKTR)
$1.47
+0.0700 ( +5.00% ) 1.3M
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Market Data
Open
$1.47
Previous close
$1.40
Volume
1.3M
Market cap
$270.51M
Day range
$1.36 - $1.50
52 week range
$0.41 - $1.93
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 13 | Apr 17, 2024 |
3 | Insider transactions | 1 | Mar 14, 2024 |
10-k | Annual reports | 97 | Mar 05, 2024 |
8-k | 8K-related | 16 | Mar 04, 2024 |
8-k | 8K-related | 16 | Mar 04, 2024 |
4 | Insider transactions | 1 | Feb 22, 2024 |
4 | Insider transactions | 1 | Feb 22, 2024 |
4 | Insider transactions | 1 | Feb 22, 2024 |
8-k | 8K-related | 14 | Feb 16, 2024 |
8-k | 8K-related | 12 | Jan 10, 2024 |